Oct. 02, 2024 8:00 AM ETAbbVie Inc. (ABBV) Per FDA requirement for this indication, Allergan Aesthetics is providing a product training program for providers, which includes facial anatomy and ...
At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
Hyaluronic acid 20mg/mL, 0.3% w/w lidocaine; injectable gel implant. Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to ...
(HealthDay)—Juvéderm Voluma XC is feasible and seems safe for correcting infraorbital hollows, according to a study published online April 5 in JAMA Facial Plastic Surgery. Michael B. Hall, M.D., from ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
(RTTNews) - Drug manufacturer AbbVie Inc. (ABBV), Tuesday announced that its subsidiary Allergan Aesthetics received approval from the U.S. Food and Drug Administration or FDA regarding Juvederm ...
Patients treated with Juvéderm Voluma XC to correct infraorbital hollows reported high satisfaction rates and experienced low rates of adverse events, according to a study. A retrospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results